Optimizing the Adult NF1 Journey: A Primary Care and Nonspecialist Guide to Surveillance Authors: Eric Legius, MD, PhD; Anna Berghoff, MD, PhD; Victor-Felix Mautner, MD, PhD; Ignacio Blanco, MD, PhD

https://www.medscape.org/viewarticle/optimizing-adult-nf1-journey-primary-care-and-nonspecialist-2026a1000zq3?page=1

The Lung Cancer Landscape: Covering Key Advances in NSCLC and SCLC Authors: Heather Wakelee, MD, FASCO; Christina S. Baik, MD, MPH; Misty D. Shields, MD, PhD

https://www.medscape.org/viewarticle/lung-cancer-landscape-covering-key-advances-nsclc-and-sclc-2026a1000zw1?page=1

DLBCL Redefined: A Case-Based Journey From Frontline Breakthroughs to Relapsed/Refractory Frontiers Authors: Gilles Salles, MD, PhD; Ayushi Chauhan, MD; Kami Maddocks, MD

https://www.medscape.org/viewarticle/dlbcl-redefined-case-based-journey-frontline-breakthroughs-2026a1000zyn?page=1

World Stage Insights: Global Advances in Targeted NSCLC Therapies Authors: Joshua Sabari, MD; Kathryn C. Arbour, MD; Balazs Halmos, MD, MS

https://www.medscape.org/viewarticle/world-stage-insights-global-advances-targeted-nsclc-2026a10010de?page=1

Lower-Risk MDS: Translating Evidence Into Community-Based Practice Authors: Hetty Carraway, MD, MBA; Mikkael A. Sekeres, MD, MS; Amer M. Zeidan, MBBS, MHS

https://www.medscape.org/viewarticle/lower-risk-mds-translating-evidence-community-based-practice-2026a100106z?page=1

Can CT Urography and Cytology Replace Ureteroscopy for Surveillance After Kidney-Sparing Surgery in Upper Tract Urothelial Cancer?

https://www.medscape.com/viewarticle/can-ct-urography-and-cytology-replace-ureteroscopy-2026a10010lg?src= A combined CT urography and urinary cytology surveillance strategy in patients managed with endoscopic kidney-sparing surgery for upper tract urothelial carcinoma would have avoided more than two thirds of ureteroscopies but missed nearly two thirds of recurrences.

Few Women Consistently Use Endocrine Therapy Post-Lumpectomy

Few Women Consistently Use Endocrine Therapy Post-Lumpectomy Many women who undergo lumpectomy for early-stage breast cancer do not adhere to endocrine therapy long term, and those who skip radiotherapy may be a particularly vulnerable group. An analysis of insurance claims found that less than 30% of patients consistently adhered to endocrine therapythroughout all 5 recommended years. And two groups were especially likely to have substantial lapses in adherence: patients younger than 60 years and those who did not receive radiotherapy post-surgery. https://www.medscape.com/viewarticle/few-women-consistently-use-endocrine-therapy-post-lumpectomy-2026a10010oq?src= American Society for Radiation Oncology (ASTRO) 2026 Annual Meeting https://www.medscape.com/c25/p14/american-society-radiation-oncology-astro-2026-annual-2026a1000rs5

Pancreatic Cancer: Is SBRT or ChemoRT Better Before Surgery? M. Alexander Otto, MMSc-PA

https://www.medscape.com/viewarticle/pancreatic-cancer-sbrt-or-chemort-better-before-surgery-2026a10010o7?src= BOSTON — What type of neoadjuvant therapy is best for patients with resectable, borderline, or locally advanced pancreatic ductal adenocarcinoma (PDAC)? While neoadjuvant therapy has become more common, the optimal type and duration of treatment remain unclear, explained William Hall, MD, radiation oncologist at the Medical College of Wisconsin in Milwaukee. American Society for Radiation Oncology (ASTRO) 2026 Annual Meeting https://www.medscape.com/c25/p14/american-society-radiation-oncology-astro-2026-annual-2026a1000rs5

Nearly 1 in 8 Cancers Worldwide Caused by Infections Frederik Joelving

https://www.medscape.com/viewarticle/nearly-1-8-cancers-worldwide-caused-infections-2026a10010mx?src= About 2.3 million cancer diagnoses in 2024, or 12% of all cases globally, were caused by infections, according to a new study from the Interna ti onal Agency for Research on Cancer (IARC). Those cancers were attributable to 12 infectious agents known to be carcinogenic to humans. At the top of list were Helicobacter pylori and human papillomavirus (HPV), which together caused roughly 1.5 million cancers worldwide in 2024. H. pylori is the primary cause of gastric cancers globally, while certain strains of HPV cause virtually all cervical cancers and contribute to several other cancer types. Meanwhile, an estimated 360,000 cancer cases were attributed to hepatitis B virus and 160,000 to hepatitis C. And in what researchers called a notable finding, Epstein-Barr virus (EBV) accounted for roughly 260,000 cancer diagnoses in 2024.

Shorter-Course Radiotherapy Is Safe Option for High-Risk Breast Cancer Dawn Attride

https://www.medscape.com/viewarticle/shorter-course-radiotherapy-safe-option-high-risk-breast-2026a10010pm?src= Locoregional recurrence remained low over 10 years in patients with high-risk breast cancer who received shorter courses of radiotherapy after mastectomy in a phase 3 trial. Among postmastectomy patients requiring regional nodal irradiation, hypofractionated radiotherapy and conventional fractionated radiotherapy showed comparable cumulative incidence of locoregional recurrence at 5 years (9.6% vs 8.6%), the primary endpoint of the trial. There were no significant differences in survival outcomes or increases in severe late adverse effects. American Society for Radiation Oncology (ASTRO) 2026 Annual Meeting https://www.medscape.com/c25/p14/american-society-radiation-oncology-astro-2026-annual-2026a1000rs5

Intralesional RNA Immunotherapy Shows Promise for BCC

https://www.medscape.com/viewarticle/intralesional-rna-immunotherapy-shows-promise-bcc-2026a10010qi?src= VIENNA — More than half of patients with high-risk basal cell carcinoma (BCC) of the head and neck (18 of 32; 56%) had no visible tumor and no viable tumor on pathology 24 weeks after three intralesional injections of the experimental RNA immunotherapy BO-112, a phase 2b trial found. The complete response rate was slightly higher among the subgroup of patients with high-risk facial lesions, at 62% (16 of 26). https://www.medscape.com/c25/p14/european-academy-dermatology-and-venereology-eadv-2026-2026a1000xdj European Academy of Dermatology and Venereology (EADV) 2026 Congress

One Target, Five Antibodies: Why Anti-CD20 Mechanism Now Decides Outcomes in Lymphoma, MS, and Lupus Nephritis

https://www.medscape.com/c99/p10/one-target-five-antibodies-why-anti-cd20-mechanism-now-2026a10010oz?src= In October 2025, obinutuzumab became the first anti-CD20 monoclonal antibody to win an FDA indication for active lupus nephritis. Gazyva PI Two earlier placebo-controlled trials of the Type I antibodies rituximab and ocrelizumab in proliferative lupus nephritis had failed to show a statistically significant benefit on renal response. Furie ARD 2022Readers should be aware of an important safety context behind the ocrelizumab trial (BELONG): it was not simply neutral on efficacy, it was stopped early by the sponsor specifically because of a safety signal, an imbalance in serious and opportunistic infections in ocrelizumab-treated patients compared with placebo, most notably a 3.2% vs 0.8% rate of serious opportunistic infections in the 400 mg ocrelizumab arm. Mysler Arthritis Rheum 2013

New Cancer Drugs: Can Care Keep Up With Innovation? Harald Müller-Huesmann, MD

https://www.medscape.com/viewarticle/new-cancer-drugs-can-care-keep-innovation-2026a10010g7?src= Breast cancer remains a major driver of innovation in oncology, not least because it is one of the largest treatment markets and is also the most common diagnosis I encounter in my daily rehabilitation work. In addition to the established oral selective estrogen receptor degrader (SERD) elacestrant, two additional oral SERDs, camizestrant and imlunestrant, are now available for patients with ESR1 mutations. Imlunestrant is approved as monotherapy for adults with estrogen receptor-positive, HER2-negative, locally advanced or metastatic breast cancer with an activating ESR1 mutation after progression on endocrine therapy.

How Scientists Finally Cracked RAS in Pancreatic Cancer Lisa Marshall

https://www.medscape.com/viewarticle/how-scientists-finally-cracked-ras-pancreatic-cancer-2026a10010ok It’s not often that slide presentations at medical conferences prompt thousands of audience members to leap to their feet, some embracing or openly weeping. But that’s what happened when pancreatic cancer specialist Brian Wolpin, MD, MPH, began to present his latest research at the American Society of Clinical Oncology meeting in Chicago this past May. A hush fell over the crowd. Wolpin began to report “a statistically significant improvement in overall survival…” Before he could finish his sentence, the audience erupted.

New Video Game Reveals How Kids With Autism Make Decisions

https://www.medscape.com/viewarticle/new-video-game-reveals-how-kids-autism-make-decisions-2026a10010g4?ecd=WNL_trdalrt_pos1_ous_261002_etid8753650&uac=148436CN&impID=8753650

How Will Personalized Care Shape Microbiome Therapies? Clara Simón

https://www.medscape.com/viewarticle/how-will-personalized-care-shape-microbiome-therapies-2026a100109z?ecd=WNL_trdalrt_pos1_ous_261001_etid8750402&uac=148436CN&impID=8750402 Changes in the gut microbiota are associated with inflammatory diseases, prompting researchers to investigate whether targeted interventions can help manage these conditions. However, evidence suggests that microbiota-based therapies may need to be tailored to individual patients rather than applied through a one-size-fits-all approach.

Dissecting the Evidence: Interpreting Recent Clinical Trial Data for Radiopharmaceutical-Based Combinations in Metastatic Castration-Resistant Prostate Cancer Authors: Bertrand Tombal, MD, PhD; Alicia K. Morgans, MD, MPH, FASCO

https://www.medscape.org/viewarticle/dissecting-evidence-interpreting-recent-clinical-trial-data-2026a10009un?page=1&src=mkmcmr_driv_stan_mscpedu_260930-OUS-HONC-dissecting-evidence-interpreting-recent-clinical-trial-data-2026a10009un-cta&uac=148436CN

Future proofing food systems The Lancet Planetary Health (+...)

Future proofing food systems The Lancet Planetary Health https://www.thelancet.com/journals/lanplh/issue/vol10no8/PIIS2542-5196(26)X2008-3

Turkish Government crackdown on HIV and LGBTQ+ groups The Lancet HIV (+...)

Turkish Government crackdown on HIV and LGBTQ+ groups The Lancet HIV https://www.thelancet.com/journals/lanhiv/issue/vol13no10/PIIS2352-3018(26)X2009-4

DTAC Bulletin: Managing Chronic Disease During Disasters

Managing Chronic Disease During Disasters According to the Centers for Disease Control and Prevention (CDC), 75 percent of U.S. adults have at least one chronic disease, such as heart disease, cancer, diabetes, epilepsy, or kidney disease.1 Because chronic conditions are so widespread, it is critical that people with chronic conditions, their families and caregivers, and emergency management personnel develop plans for managing these conditions during disasters. Explore the resources below to learn more about how you or your loved ones with chronic diseases can prepare for disasters. Federal Guidelines for Opioid Treatment Programs Opioid use disorder (OUD) is a chronic medical condition for which uninterrupted access to treatment is especially important during disasters. The Federal Guidelines for Opioid Treatment Programs (pages 21–22) offer recommendations to help maintain continuity of care, access to medications, patient communication, and support for individuals affected by transportation or mobility challenges during emergencies. After the Storm: Managing Chronic Conditions after a Natural Disaster https://www.cdc.gov/natural-disasters/media/pdfs/2024/managing-chronic-conditions-after-natural-disaster-508.pdf?utm_source=SAMHSA&utm_campaign=72da689e88-EMAIL_CAMPAIGN_2026_05_26_01_18_COPY_01&utm_medium=email&utm_term=0_-d5b39b5406-167840245 This CDC tip sheet discusses what to do following a disaster for those with a chronic condition. Conditions covered include Alzheimer’s disease, cancer, diabetes, heart disease, and mental health conditions. This resource also includes QR codes to materials with further information. Planning for Emergencies: A Guide for People with Kidney Disease https://nkfm.org/wp-content/uploads/2024/02/NKF-Planning-for-Emergencies-A-Guide-for-People-with-CKD.pdf?utm_source=SAMHSA&utm_campaign=72da689e88-EMAIL_CAMPAIGN_2026_05_26_01_18_COPY_01&utm_medium=email&utm_term=0_-d5b39b5406-167840245 More than 35.5 million adults in the United States have chronic kidney disease.2 This guide, provided by the National Kidney Foundation, offers information and forms that people with chronic kidney disease and their loved ones can use to prepare for disasters. The guide provides general preparedness tips for people with kidney disease, steps to take after a natural disaster, and diet recommendations for people who use dialysis to manage chronic kidney disease and cannot access dialysis services during or after a disaster. Emergency Preparedness for Older Adults and People With Disabilities The Administration for Community Living (ACL) designed this poster to help people prepare for emergencies. It highlights how to prepare electric medical devices for power outages, the importance of creating a network of support, and what to include in an emergency preparedness kit. ACL also offers a medical information card that can be printed and included in emergency preparedness kits for those living with chronic illnesses or disabilities. Questions About the SAMHSA DTAC Bulletin? The SAMHSA DTAC Bulletin is a monthly newsletter used to share updates in the field, post upcoming activities, and highlight new resources. For more information, please contact: Anne Genet Reim, M.P.H. 202–713–7866 anne.reim@samhsa.hhs.gov CDR Katie Hager, M.S., B.S.N., RN 240–276–1268 katie.hager@samhsa.hhs.gov About Chronic Diseases https://www.cdc.gov/chronic-disease/about/index.html?utm_source=SAMHSA&utm_campaign=72da689e88-EMAIL_CAMPAIGN_2026_05_26_01_18_COPY_01&utm_medium=email&utm_term=0_-d5b39b5406-167840245 Fast Facts: Health and Economic Costs of Chronic Conditions https://www.cdc.gov/chronic-disease/data-research/facts-stats/index.html?utm_source=SAMHSA&utm_campaign=72da689e88-EMAIL_CAMPAIGN_2026_05_26_01_18_COPY_01&utm_medium=email&utm_term=0_-d5b39b5406-167840245

Why stem cell-like T cells are shaping the next generation of CAR-T therapies A rare immune cell subset with the capacity to self-renew, persist long-term, and drive potent antitumor responses. Written byAndrea Corona

Why stem cell-like T cells are shaping the next generation of CAR-T therapies A rare immune cell subset with the capacity to self-renew, persist long-term, and drive potent antitumor responses. Written byAndrea Corona https://www.drugdiscoverynews.com/why-stem-cell-like-t-cells-are-shaping-the-next-generation-of-car-t-therapies-17245?utm_campaign=DDN_Newsletter_Dose&utm_medium=email&_hsenc=p2ANqtz--efgamE1Gmy4uyIgUR7nBO6A5uyXHmPHWqmd3uptexQwEX84SHCBeLKx-ySiqNdpXSAlX7LT9bPRyGfKirF8qTy_KRgg&_hsmi=442044179&utm_content=442044179&utm_source=hs_email CAR-T cell therapy has transformed outcomes in certain blood cancers, but it has always carried the fundamental vulnerability that the cells that make it work do not always last. Infused T cells can expand, contract, and exhaust, in turn leaving patients who initially responded without the sustained immune pressure needed to prevent relapse. Understanding why some patients maintain durable remissions while others do not has pointed the field toward a rare immune cell subset that may hold the answer. Stem cell-like memory T cells, known as Tscm cells, occupy a unique position in the T cell differentiation hierarchy. Phenotypically resembling naive T cells, they are in fact the least differentiated of the memory T cell subpopulations, sitting at the apex of the memory hierarchy as progenitors capable of giving rise to all downstream memory and effector subsets. Their defining properties, such as self-renewal, long-term persistence, and potent antitumor activity, make them a compelling foundation for cell therapies that need to outlast the tumor.

Stem cell discovery opens nonsurgical era for lumbar spinal stenosis Scientists identified stem cells whose dysregulated calcium signaling drives the degenerative condition, opening the door to novel treatments. Written byPriyom Bose

Stem cell discovery opens nonsurgical era for lumbar spinal stenosis Scientists identified stem cells whose dysregulated calcium signaling drives the degenerative condition, opening the door to novel treatments. Written byPriyom Bose https://www.drugdiscoverynews.com/stem-cell-discovery-opens-nonsurgical-era-for-lumbar-spinal-stenosis-17561 When a thin ligament in the spine thickens and bulges into the central canal, it compresses spinal nerves and leads to pain, numbness, and mobility issues. That’s what happens in lumbar spinal stenosis (LSS), which affects an estimated 103 million people worldwide.

Resources for Your Rural Maternal Health Network

Resources for Your Rural Maternal Health Network Tools and guidance to help build networks, implement innovative strategies, and use data to improve maternal health outcomes in rural communities https://ruralmaternaldata.org/?utm_medium=email&utm_source=govdelivery The HRSA-funded Rural Maternal Health Data Support program launched a new tool for creating customized maternal health profiles for counties across all 50 states and Washington, DC. Users can select one or more counties to explore combined indicators on demographics, health care provider capacity, maternal health outcomes, and hospital obstetric services. Profiles include state and national comparisons, county-level maps of obstetric service availability, and full source citations to support maternal health planning and analysis.

Free Continuing Education Credits for Healthcare Professionals

Free Continuing Education Credits for Healthcare Professionals Healthcare providers can now earn free continuing education (CE) credits while learning how to recognize and address the harms associated with screen use in children and adolescents. https://www.hhs.gov/surgeongeneral/reports-and-publications/screen-use-harms/index.html?utm_medium=email&utm_source=govdelivery#free-continuing-education Healthcare providers can now earn free continuing education (CE) credits while learning to recognize and address harms associated with screen use among children and adolescents. The Office of the Surgeon General, in partnership with the American College of Preventive Medicine (ACPM), offers 1.5 AMA Category 1 Credits™ for the Screen Use Advisory and 1 credit for the accompanying Toolkit. Eligible providers can register with ACPM to earn credits while accessing evidence-based guidance and practical resources.

Downloadable Resource for Parents: The Magic TabletThe Magic

Downloadable Resource for Parents: The Magic TabletThe Magic Tablet is designed as a companion to the Surgeon General’s advisory on the harms of screen use, encouraging children and adolescents to get off screens and live real life. https://www.hhs.gov/surgeongeneral/reports-and-publications/screen-use-harms/index.html?utm_medium=email&utm_source=govdelivery#magic-tablet

Webinar October 13, 12:00 – 1:00 pm ET Strengthening Rural Behavioral Health Care Access Through a Community-Based Workforce

https://www.chcs.org/resource/strengthening-rural-behavioral-health-care-access-through-a-community-based-workforce/?utm_campaign=017935fc37-Access+Rural+BH+Webinar_9%2F9%2F2026&utm_medium=email&utm_source=govdelivery&utm_term=0_-017935fc37-493395962 The Center for Health Care Strategies (CHCS) will host a webinar on Tuesday, October 13, 2026, at 12:00 PM ET, highlighting community-based workforce models expanding rural behavioral health care in Georgia, North Carolina, and Tennessee. Speakers will discuss integrating peer support specialists, community health workers, and community paramedics into care teams, with practical insights on program design, recruitment, sustainability, and implementation. The webinar draws on provider experiences and findings from an upcoming CHCS brief.

Maternal Suicide Prevention Strategies October 6, 2026 10:30 am - 11:30 am Pacific Time

https://secure.everyaction.com/7TlpBtZVi0mZVATbB6Lt0g2?ceid=24196946&emci=fcbb1e8e-a7a8-f111-9b33-0022482a933b&emdi=084af609-cbab-f111-9b33-0022482a933b&utm_medium=email&utm_source=govdelivery Maternal Suicide Prevention Strategies This Policy Center for Maternal Health webinar invites obstetric providers, maternal mental health specialists, suicide prevention leaders, and perinatal psychiatrists to advance evidence-based maternal suicide prevention strategies and improve crisis response systems for pregnant and postpartum individuals. The session will address the role of depression as an indicator of suicide risk, and treatments, including a discussion about medications and black box warnings, among other topics. Held Tuesday, October 6, 2026, at 12:30 PM ET.

National Lead Poisoning Prevention Week

https://www.epa.gov/lead/national-lead-poisoning-prevention-week?utm_medium=email&utm_source=govdelivery National Lead Poisoning Prevention Week (NLPPW) takes place October 25–31 during Children’s Health Month. This year’s theme, “Keep Kids Safe From Lead,” focuses on raising awareness and educating communities about preventing childhood lead exposure. NLPPW brings together individuals, organizations, industry, and state, tribal, territorial, and local governments. The CDC, EPA, and HUD have collaborated to provide comprehensive resources that help communities increase awareness, support prevention efforts, and protect children from the harmful effects of lead exposure.

Breast Cancer Awareness Month (+...)

https://www.cdc.gov/breast-cancer/?utm_medium=email&utm_source=govdelivery Observed each October, Breast Cancer Awareness Month promotes awareness of breast cancer and the importance of early detection. Breast cancer accounts for nearly one in three new cancer cases among women, and approximately one in eight women in the United States will develop breast cancer during her lifetime.

Association between COVID-19 by variant period and delivery-related outcomes in the United States Deborah Kilday ,Michael Korvink,Drew Tatum,Zhun Cao,Ning Rosenthal,Raymond Perigard,Ashley Finke,Richelle Marshall,Margaret Snyder,Kelly Larson,Alain Moluh,Stephanie Martin,Samantha Sommerness,

https://journals.plos.org/plosone/article?id=10.1371%2Fjournal.pone.0355223&utm_medium=email&utm_source=govdelivery OWH Research Examines COVID-19 and Delivery-Related Outcomes Across Variant Periods Study A new study supported by the HHS Office on Women’s Health examined associations between COVID-19 infection and delivery-related outcomes during different COVID-19 variant periods in the United States. Published in PLOS ONE, the study analyzed more than 2.5 million delivery-related hospitalizations from April 2020 through March 2023. More than 53,000 of these hospitalizations involved a COVID-19 diagnosis, providing researchers with data to assess maternal delivery outcomes across multiple phases of the pandemic and variant periods nationwide.